obesity

There are many benefits to maintaining strong metabolic health, including weight management, a strong immune system, and reduced risk for chronic disease. But what does your metabolic health have to do with your sexual health? Ask a Sexpert! In this video, Dr. Taylor Kohn unpacks the impact of...

Semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Zepbound and Mounjaro, are new therapies for weight loss that actually work, helping millions around the world to feel better. But some people are fearful of side effects, such as loss of muscle mass. Are their fears warranted...

* Dr. le Roux shares exclusive insights into the Phase 3 data for #Survodutide (Boehringer Ingelheim’s dual GLP-1/glucagon agonist), including its groundbreaking impact on visceral fat and #FattyLiverDisease (MASLD/MASH) via the SYNCHRONIZE trials. In this #DoctorPodcasts Episode 149, we...

Truly impressive! * the really exciting data of SYNCHRONIZE-1 was not the weight loss it was actually the metabolic health gains so we see that there was an improvement in glycemia and blood pressure but there was a. 63% REDUCTION IN FAT IN THE LIVER so imagine you had 16% weight loss but 25%...

Carel le Roux is a Professor of Experimental Pathology at University College Dublin, Director of the Metabolic Medicine Group, and one of the world's leading researchers on how the gut communicates with the brain. He completed his PhD at Imperial College London, where he conducted foundational...

Nature staff discuss preliminary data on the effects of GLP-1 drugs on male fertility, plus a two-year trial of a brain-computer interface. Timestamps 00:18 Brain-computer interface makes a life-changing impactNature: At-home brain implant gives man with motor neuron disease his daily life...

Incretin-Based Therapies Goals for Today

, discusses : : . ,

Dr. Andres Guillen Lozoya discusses findings from, "Testosterone Levels Improve in Men under GLP-1 Receptor Agonist Therapy.” This study aimed to evaluate changes in total and free testosterone before and after GLP-1RA therapy in men

In this episode of Science Quickly, Scientific American’s associate health editor Lauren Young joins host Kendra Pierre-Louis to talk about how the story of GLP‑1 drugs such as Ozempic, Wegovy and Mounjaro is evolving. We trace GLP-1s’ origins as type 2 diabetes treatments, their rise as...

Are GLP-1 agonists like Ozempic and Mounjaro the future of healthcare or a risk to your health? We break down the latest data on weight loss medication efficacy, common side effects, and the truth about muscle mass loss (sarcopenia). In This Episode: Dr. Jordan Feigenbaum and Dr. Austin...

In this video, David Kerr, MD examines the complex relationship between GLP-1 receptor agonists and gastrointestinal health. While these agents are highly effective for treating type 2 diabetes and obesity, a large-scale meta-analysis of over five million individuals suggests a nuanced...

Dr. Corona another powerhouse in the field! * The current video summarizes and critical analyzes available evidence from the first reports to a recently updated meta-analysis [1]. Data derived from a meta-analytic approach, including 25 studies and 18,237 subjects showed that MetS was...

In this SCCR Science Series session, Elaine Costa, MD, a postdoctoral scholar in the Department of Otolaryngology, Head, and Neck Surgery (OHNS) provides an overview of obstructive sleep apnea (OSA). Here she covers:

Professor Michael Zitzmann Testosterone Deficiency (TD). and its Effects https://www.excelmale.com/threads/the-male-hormone-reset-how-glp-1ras-lifestyle-and-testosterone-transform-obesity-linked-problems.33386/

What actually makes a GLP-1 pill work in the real world—and why does taking it come with such specific rules? And if these meds improve health beyond weight, why does the conversation still get stuck on the scale?Dr. Emily Cooper, Mark Wright, and Andrea Taylor sit down with Novo Nordisk’s Dr...

Dr. Peter Wilson I am going to give you some pearls from recent talks. 1:28-2:19 * Shehzad Basaria from Harvard who's on the TRAVERSE Trial. He said one of the biggest mistakes were making is assuming free testosterone is correct. Thats important and I think we in endocrinology and urology...

Think sleep apnea is just for "middle-aged men who snore?" Think again. Dr. Kimberly Sterling and Dr. Audrey Wells join us to reveal why 90% of women are living with undiagnosed sleep apnea and how "invisible" symptoms like fatigue and anxiety are masking a life-threatening breathing disorder.

* we discuss what a recently rolled-out GLP-1 pill, the first of its kind approved for obesity, could mean for the future of weight loss. Drugs known as glucagon-like peptide-1 receptor agonists, colloquially called GLP-1 medications, have gone from relatively obscure diabetes...

In this episode, Dr. Spencer Nadolsky discusses the transformative role of GLP-1 medications in obesity treatment. He explains the mechanism of GLP-1, its rise in popularity, associated risks, and the importance of personalized medicine. The conversation also touches on the significance of...

* The anticipated lower cash price – reported at approximately $149 – could substantially improve access, particularly compared with injectable GLP-1–based weight loss therapies. The hosts discuss patient preferences, noting that an oral option may appeal to individuals hesitant about injections...

New drug candidates could transform the obesity treatment landscape again, as pill formulations and multi-agonist treatments undergo clinical trials. Endocrine Society experts Priya Jaisinghani, MD, DABOM, and Mehmet Furkan Burak, MD, discussed how emerging treatments could improve obesity...

Figure 1. Comparative overview of therapeutic approaches for male hypogonadism and metabolic dysfunction. The figure summarizes the key advantages and disadvantages of three main management modalities: GLP-1 receptor agonists (GLP-1 RAs), lifestyle modification (diet and exercise), and...

https://www.obesity-abstracts.org/ob/0005/ob0005oc1 Background Male obesity-related secondary hypogonadism (MOSH) affects two-thirds of men with BMI ≥40 kg/m2 and is associated with increased mortality. Animal models suggest decreased hypothalamic function in obesity-related hypogonadism...

Are you up to date on emerging pharmacologic therapies transforming obesity and type 2 diabetes care?

Takeaway Messages

In this episode of On the Edge of Breakthrough, host Dr. Monty Pal sits down with Dr. Charles Brenner, an internationally recognized expert in metabolism and the founding Chair of the Department of Diabetes & Cancer Metabolism at City of Hope. Together, they explore the metabolic links between...

* Among the human studies, 9 evaluated testosterone levels (total and/or free), 6 reported on gonadotropins (LH, FSH), and 5 assessed clinical hypogonadal symptoms such as libido and erectile function. In total, 7 human studies demonstrated a statistically significant increase in testosterone...

https://diabetesjournals.org/diabetes/article/74/Supplement_1/1966-LB/158768/1966-LB-Efficacy-and-Safety-of-Semaglutide-7-2-mg Introduction https://sciencehub.novonordisk.com/congresses/ada2025/Lingvay.html

In this episode of You Are Not Broken, Dr. Kelly Casperson sits down with endocrinologist and obesity medicine expert Dr. Rocio Salas-Whalen for a deep dive into GLP-1 medications (like Ozempic, Wegovy, and Mounjaro). They cover everything you should be asking but probably haven’t heard...

GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in...